Pharma Pioneer

YourChoice Therapeutics Board Member Presents Male Contraceptive Phase 1a Study at ACS Spring 2024

19 May 2024
2 min read

Gunda Georg, co-creator of YCT-529, presented an update on the phase 1a clinical trial of the novel hormone-free male contraceptive pill at the American Chemical Society's Spring Meeting in New Orleans, concluding on March 21, 2024. The drug, developed by San Francisco-based biotech startup YourChoice Therapeutics, began its phase 1 study in December 2023, focusing on the safety, tolerability, and pharmacological properties of YCT-529 in a group of 16 participants. The study is anticipated to be completed by mid-2024.
Dr. Georg, a distinguished professor and director at the University of Minnesota, highlighted the significance of contraceptive equity and the shared responsibility in pregnancy prevention. YCT-529 operates by inhibiting sperm production through the blocking of retinoic acid, a form of vitamin A, in the testes. Preclinical studies have demonstrated its effectiveness and complete reversibility without side effects.
Akash Bakshi, CEO of YourChoice Therapeutics, emphasized the demand for hormone-free birth control options and the potential impact of YCT-529 on reproductive equality. The company, established in 2018, is currently conducting the phase 1a trial of YCT-529 and aims to apply its therapeutic platform to develop hormone-free contraceptive products for women as well. YourChoice Therapeutics has received significant funding, including a $15M Series A round in 2022, and is collaborating with Dr. Georg and the Male Contraceptive Initiative to advance the clinical trial.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

FDA Approves DepYmed's Phase 1 Trial for Rett Syndrome Drug DPM-1003
Pharma Pioneer
2 min read
FDA Approves DepYmed's Phase 1 Trial for Rett Syndrome Drug DPM-1003
19 May 2024
DepYmed Inc. has announced that it has obtained approval from the U.S. Food and Drug Administration (FDA) to begin phase 1 clinical trials for DPM-1003.
Read →
Recce Pharma Concludes Phase I/II Dosing for RECCE® 327 in UTI and Urosepsis Trial
Pharma Pioneer
3 min read
Recce Pharma Concludes Phase I/II Dosing for RECCE® 327 in UTI and Urosepsis Trial
19 May 2024
Recce Pharmaceuticals has recently completed a new phase of clinical trials for its lead drug candidate, RECCE® 327.
Read →
Promising Early Results: Deltacel-01 Trial Stabilizes Lung Tumor and Clears Brain Metastases in Patient Two
Pharma Pioneer
3 min read
Promising Early Results: Deltacel-01 Trial Stabilizes Lung Tumor and Clears Brain Metastases in Patient Two
19 May 2024
The trial is assessing the efficacy of Deltacel™ (KB-GDT-01), an allogeneic, readily available Gamma Delta T-cell (GDT) therapy for patients with stage 4 metastatic non-small cell lung cancer (NSCLC).
Read →
Jasper Initiates SPOTLIGHT Trial with First Patient Dosed for CIndU Treatment with Briquilimab
Pharma Pioneer
2 min read
Jasper Initiates SPOTLIGHT Trial with First Patient Dosed for CIndU Treatment with Briquilimab
19 May 2024
Biotechnology firm Jasper Therapeutics has initiated its Phase 1b/2a clinical trial, for the treatment of chronic inducible urticaria (CIndU) using a novel antibody, briquilimab.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.